Companies › Estrella Immunopharma
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| EB103 Autologous T-cell therapy transduced with lentiviral vector expressing the EB103 transgene | – | Phase 1 | B-Cell Non-Hodgkin's Lymphoma (NHL) | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06343311 | EB103 | Phase 1 | B-Cell Non-Hodgkin's Lymphoma (NHL) | Oncology | Jul 2027 |
Cash of $0m on 2026-06-30; operating cash outflow about $17m a year; runway about 0 months at that burn, to Jul 2026
Press releases filed as 8-K in the last year:
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.